
|Videos|April 9, 2021
Visus presbyopia drop gets FDA IND OK
A presbyopia-correcting eyedrop recently received FDA acceptance of its investigational new drug (IND) application
Advertisement
Rhett Schiffman, MD, MHSA, chief medical officer and head of research and development at Visus Therapeutics, talks with Gretchyn Bailey, NCLC, FAAO, editor in chief of Optometry Times® about Brimichol, the company’s presbyopia-correcting eyedrop that recently received FDA acceptance of its investigational new drug (IND) application.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Optometry Times - Clinical News & Expert Optometrist Insights
1
Retinal ganglion cells: What they can tell us and why we should listen
2
Dompé enrolls first patients in phase 3 trial of Isocyclosporin for atopic keratoconjunctivitis
3
What advancements optometrists are hoping for in 2026
4
Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA
5








































